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Abstract The endocannabinoid system via cannabinoid
(CB: CB1 and CB2) receptors and their endogenous ligands
is directly and indirectly involved in many physiological func-
tions, especially in memory and learning processes. Extensive
studies reported that this system strictly modulates cognition-
related processes evaluated in various animal models.
However, the effects of cannabinoids on the cognition have
been contradictory. The cannabinoid compounds were able to
both impair or improve different phases of memory processes
through direct (receptor related) or indirect (non-receptor
related) mechanism. The memory-related effects induced by
the cannabinoids can be depended on the kind of cannabinoid
compound used, dosage, and route of administration as well as
on the memory task chosen. Therefore, the objectives of this
paper are to review and summarize the results describing the
role of endocannabinoid system in cognition, including
various stages of memory.
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ORT Object recognition task
PA Passive avoidance
PCR Polymerase chain reaction
PEA Palmitoylethanolamide
RAM Radial arm maze
VTA Ventral tegmental area
WMT Water maze test
Pharmacology of the Endocannabinoid System
The endocannabinoid system (ECS) is a lipid signaling
system, which is functionally active since the early stages of
brain development and remains active during both prenatal
and post-natal life [1–3]. This system consists of the cannabi-
noid (CB) receptors, their endogenous ligands, the enzymes
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for the synthesis and degradation of endocannabinoids, and
the reuptake transport system [4].
The discovery of specific CB receptors, followed by iden-
tification of their endogenous ligands, gave an opportunity to
the extensive research on the significance of this system for
the proper functioning of the organism. CB receptors were
discovered in late 1980s and then were divided into two dif-
ferent subtypes of G protein-coupled receptors [5]. Currently,
two types of CB receptors are known. The pharmacological
effects are mainly exerted through the activation of Gi/o
protein-coupled membrane receptors CB1 and CB2. Despite
the fact that both CB1 and CB2 receptors belong to the group
of G protein-coupled receptors and are characterized by sig-
nificant homology, they differ in their function and specificity
of cellular expression [6].
CB1 receptors are located mainly in the central nervous
system (CNS), and they are one of the most abundantly
expressed neuronal receptors in the CNS, which suggests their
important role in the function of the CNS. These receptors are
widely expressed in multiple brain areas with the highest con-
centration in the regions associated with cognition and move-
ment like amygdala, hippocampus, septum, brain cortex,
globus pallidus, substantia nigra, cerebellum, and lateral cau-
date putamen [4]. Additionally, they are also present at lower
concentration in a variety of peripheral tissues, both on sen-
sory nerve fibers and in the autonomic nervous system [6–8].
CB1 receptors are localized presynaptically on glutamatergic
and gamma-aminobutyric (GABA) acid axon terminals [9]. In
the hippocampus, CB1 receptors are located mainly in
GABA-ergic, inhibitory interneurons. They are also present
in the hippocampal glutamatergic axon terminals, but their
concentration is at least 20 times lower than in the presynaptic
areas of this brain structure. Activation of CB1 receptors is
connected with inhibition of adenyl cyclase as well as calcium
channels and leads to activation of potassium channels; thus, it
contributes to short-term depression of neurotransmitter re-
lease in corticostriatal GABA-ergic and glutamatergic neurons
[5]. CB1 receptors are also present on noradrenergic termi-
nals, and their blockade increases release of norepinephrine
in limbic regions [10, 11]. Owing to their localization, CB1
receptors control both cognitive process and emotional behav-
ior, including stress, fear, or anxiety [12–17] by modulating
neuronal signaling and synaptic plasticity [18].
In turn, CB2 receptors are present mainly peripherally and
are the most abundant in the immune system in a variety of
immune cells including B lymphocytes, natural killer cells,
monocytes, macrophages, polymorphonuclear neutrophils,
and T cells [4, 6]. Thus, they are mainly involved in immune
system functions [6, 19]. However, the CB2 receptors have also
been found in microglial cells in the CNS. The gathered data
suggests that CB2 receptors modulate neuronal function and
play a role in psychiatric disorders. Polymorphism of CB2
receptor gene encoding CB2 receptors in humans is related to
schizophrenia [20, 21], depression [22], and bipolar disorders
[23]. Moreover, in CB2-knockout mice, schizophrenia-like
symptoms were observed [24]. Additionally, the CB2 receptors
modulate both excitatory [25, 26] and inhibitory synaptic trans-
missions in the hippocampus [27–29]. It has been reported that
the activation of CB2 receptors reduces pain [30], impulsive
behavior [31], locomotor activity of rodents [22, 32, 33], and
vomiting of ferrets [34]. Stimulation of CB2 receptors also
decreases the excitability of peripheral sensory neurons [30],
cortical pyramidal neurons [35], and dopaminergic neurons in
the ventral tegmental area (VTA) [36] (Fig. 1).
As mentioned earlier, endocannabinoids are synthesized on
demand from lipid precursors derived from the enzymatic
cleavage of cell membrane constituents in response to neuronal
membrane depolarization or immune cell activation and are
released from post-synaptic membranes as retrograde messen-
gers onto presynaptic terminals of excitatory or inhibitory char-
acter, thus suppressing both inhibitory and excitatory signaling
within specific neuronal area. Endocannabinoids control syn-
aptic plasticity by an influence on neurotransmitter release [5,
6, 18]. They have affinity for both CB1 and CB2 receptors [6].
Henceforth, two endogenous cannabinoids (endocannabinoids)
were discovered: arachidonoylethanolamide (anandamide
(AEA)) and 2-arachidonoylglycerol (2-AG) [5]. They remain
the two most studied endogenous substances from the others
known so far, including virodhamine, noladin ether,
palmitoylethanolamide (PEA), N-arachidonoyl dopamine
(NADA), N-arachidonylglycine (NAGly), oleamide, and
oleoylethanolamine (OEA) [37] (Table 1).
2-AG is mainly produced in the CNS, andAEA is produced
at low levels in the periphery and the CNS [38]. Production of
endogenous cannabinoids is increased in response to patho-
genic stimulus. Particularly important to immune modulation
is a fact that the production of endocannabinoids is stimulated
by activation of immune cells (macrophages) and dendritic
cells, and stimulated immune cells have reduced the expres-
sion of endocannabinoid-degrading enzymes [39].
Endocannabinoids are metabolized by degradative enzymes
like fatty acid amid hydrolase (FAAH), which metabolizes
AEA as well as 2-AG, and monoacylglycerol lipase
(MAGL), which metabolizes 2-AG [8].
It should be also noted that there are two novel G protein-
coupled orphan receptors GPR55 and GPR119, which have
been recently defined as CB receptors [40]. Though showing
virtually no apparent homology to either of the classical CB
receptors, GPR55 was identified as a novel CB receptor [41].
The CB-sensitive receptor GPR55was identified and cloned by
Sawzdargo et al. [42]. Its presence in the brain, including the
hippocampus, has been proved by using quantitative polymer-
ase chain reaction (PCR) [43, 44]. GPR55 activity can be mod-
ulated by phytocannabinoids and endocannabinoids [38, 44].
The endocannabinoids that have affinity for GPR55 receptors
probably include AEA, 2-AG, PEA, and others [45].Moreover,
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Fig. 1 The distribution of CB
receptors in the CNS and
periphery



































recent studies suggest that L-α-lysophosphatidylinositol, which
activates GPR55 but not CB1 or CB2 receptors, could also be
its endogenous ligand [46, 47]. Contrariwise, cannabidiol
(CBD), a major constituent of Cannabis sativa, is a GPR55
antagonist, with low affinity for CB1 receptors [44, 48]. In turn,
GPR119 receptors are expressed on enteroendocrine L cells of
the gastrointestinal tract. They regulate the release of the anti-
diabetic peptide glucagon-like peptide-1 [49–51]. These recep-
tors are also found on pancreatic β cells in the islets of
Langerhans. OEA is one of the most potent ligands for these
receptors, but they are not activated by AEA and only weakly
by PEA [41]. However, the pharmacology of both GPR55 and
GPR119 is enigmatic, and its adaptive role in the brain remains
unknown. Therefore, the explanation of their exact role in the
ECS requires further studies.
As we described previously, the ECS, through CB recep-
tors, and its interactions with a multitude of neurotransmitters











































physiological and physical functions [52–61]. In the recent
years, a large number of studies focused on learning and mem-
ory processes. The substances exerting their action through
ECS are able to both impair and enhance different phases of
memory formation through direct and indirect mechanisms.
However, the results of multiple studies show that manipula-
tions performed on the ECS in reference to learning and mem-
ory bring contradictory results. Thus, the purpose of this paper
is to review and summarize findings connected with the in-
volvement of the ECS in the different memory stages.
The Role of CB Receptor in the Memory-Related
Responses in Animal Models of Memory: CB
Receptor Agents
CB1 Receptor Ligands
The influence of the CB1 receptor ligands on memory and
learning processes has been widely documented by various
experiments and clinical studies [8, 62–66]. Nevertheless,
the results are still contradictory. In this part of the present
elaboration, we will summarize the effects of the CB1 receptor
ligands, including CB1 receptor agonist and CB1 antagonists
(and inverse agonists) on different memory stages.
Studies have demonstrated that an acute administration of
synthetic CB1 receptor agonists: CP55940 and HU-210 atten-
uated acquisition of memory in various animal models, e.g.,
the water maze test (WMT), the object recognition task
(ORT), and the contextual fear conditioning (CFC) test
[67–71]. Similarly, Mazzola et al. [68] and others [71] con-
firmed these effects of direct activation of natural CB1 recep-
tor agonist—Δ9-tetrahydrokannabinol (Δ9-THC). Δ9-THC
(3.0, 5.0, and 6.0 mg/kg) injected intra-peritoneally (i.p.)
30min before the learning trial significantly impairedmemory
acquisition using the passive avoidance (PA) task in rats. This
deterioration was reversed by pretreatment with 1 mg/kg of
rimonabant (SR141716A), a CB1 receptor antagonist.
Moreover, indirect stimulation of CB1 receptors impaired ac-
quisition of memory in the recognition memory test [72].
In turn, Pamplona and Takahashi investigated whether
CB1/CB2 receptor agonist,WIN 55,212-2, is able to influence
the acquisition of fear conditioning using tone and contextual
versions [69]. They revealed that this compound (2.5 and
5.0 mg/kg, i.p.), administered before conditioning and before
testing, impaired memory processes in the CFC and did not
affect the freezing behavior induced by tone presentation;
therefore, non-state-dependent effects of WIN 55,212-2 on
tested animals were observed. During the course of further
studies, selective CB1 antagonists (SR141716A and
SR147778) were administered, in order to establish whether
impaired contextual conditioning would be prevented.
Preadministration of SR141716A (1.0 mg/kg, i.p.) or
SR147778 (1.0 mg/kg, i.p.) has in fact prevented the impair-
ment. These findings demonstrate that an acute administration
of WIN 55,212-2 dose-dependently impairs the acquisition of
memory in the CFC test, which is a hippocampus-dependent
learning and memory task and does not affect tone fear con-
ditioning, which is considered independent of the hippocam-
pus [73, 74]. Likewise, chronic administration of WIN
55,212-2 significantly impaired spatial memory in rats evalu-
ated in the WMT [75]. Additionally, Kruk-Slomka et al. [64]
revealed that WIN 55,212-2 impaired both acquisition and
consolidation of memory in PA test in mice. The evidence
gathered from this experiment reaffirms that the effects of
the CB receptor agonists are selective for the hippocampus-
dependent aversive memories in rats.
Contradictory data concerning the influence of CB1 on
memory consolidation has also been reported. It has been
demonstrated that post-training administration of CB1 recep-
tor agonist HU-210 as well as a combined CB1/CB2 receptor
agonist WIN 55,212-2 attenuated consolidation of memory in
the CFC test, the WMT, and the ORT [7, 76–78]. Indeed,
Maćkowiak et al. [77] investigated the role of CB1 receptors
in hippocampal-dependent memory consolidation using HU-
210. The results indicated that HU-210 impaired the consoli-
dation of fear memory in the CFC test. These detrimental
effects were abolished by a CB1 receptor antagonist
AM251. These findings may suggest the involvement of
CB1 receptors in memory and learning processes. The results
of the studies indicated also that AM251 blocked the effects of
HU-210 on freezing behavior but did not affect memory con-
solidation in the CFC on its own. Thus, the blockade of CB1
receptors does not affect consolidation of contextual memory
[79] and disrupts memory consolidation in a step-down inhib-
itory avoidance (IA) [80, 81].
Similar effects of WIN 55,212-2 on memory consolidation
were observed in spatial memory formation using the WMT
[78]. Yim et al. administered WIN 55,212-2 systemically and
intra-cranially to assess both methods of drug delivery. They
demonstrated that this CB1/CB2 receptor ligand impairs the
consolidation of long-term spatial memory. Similar long-term
memory impairments were observed in both systemic injec-
tions and intra-hippocampal infusions of WIN 55,212-2. As
CB2 receptors are not expressed in the hippocampus, there-
fore, the observed impairments provide an indirect support
that this effect was reached by targeting CB1 receptors [78].
Nonetheless, it has been noted that intra-basolateral amygdala
(intra-BLA infusion) of WIN 55,212-2 facilitated memory
consolidation in rats evaluated in the IA task or had no effect
in the mentioned animal model [82, 83]. On the other hand,
post-training intra-hippocampal injection of this drug im-
paired consolidation of memory in several behavioral tasks
[84]. WIN 55,212-2 was also evaluated in the experiments
conducted by Clarke et al. [76]. They examined the effects
of post-training activation of hippocampal CB receptors on
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the consolidation of object recognition memory. The results of
the study were in agreement with the evidence provided by
Yim et al. [78]. WIN 55,212-2 impaired the consolidation
phase of memory formation. Amnestic effect of this com-
pound was completely reversed by coadministration of CB1
receptor antagonist, AM251, as well as mimicked by CB1
receptor agonist, ACEA, but not by CB2 receptor agonist,
JWH-015 [78]. These findings are also in agreement with
the results published by Moshfegh et al. [85]. They used a
step-down PA task as a model of learning. The results indicat-
ed that post-training administration of WIN 55,212-2 pro-
duced an amnestic response. All the effects described previ-
ously endorsed the hypothesis that the memory impairments
were due to activation of hippocampal CB1 receptors.
Systemic administration of CB1 receptor antagonists, e.g.,
rimonabant (SR141716A) or AM251, has been tested in var-
ious learning paradigms alone or coadministered with CB1
agonists [61, 63, 64, 81, 86–89].
SR141716A is a selective and potent CB1 receptor antago-
nist [90]. It also presents features of an inverse agonist [91]. An
acute, pretraining administration of SR141716A facilitated the
acquisition of memory in rodents observed in the PA test, the
elevated T-maze (ETM) test, and social recognition memory
task [61, 89] and impaired the acquisition of memory assessed
in the spatial memory test [92]. Additionally, systemic, post-
training administration of rimonabant enhanced memory con-
solidation in the radial arm maze (RAM) [89]. Also, Robinson
et al. studied the effects of SR141716A on spatial learning and
memory formation using the WMT [92]. Two experiments
were performed. In the first one, rimonabant was administered
i.p., before or immediately after training. The results indicated
that systemic administration before training induced deficits in
acquisition of spatial reference memory; however, pretraining
before drug treatment eliminated this effect. The experiment
revealed that rimonabant-induced memory deficits appeared
as a result of anxiogenic effects of the drug. Post-training injec-
tions had no effect. In the second experiment, rimonabant was
administered intra-hippocampally during the training and the
results indicated that this drug enhanced acquisition learning
and exerted no effect on consolidation of memory.
Subcutaneous injections did not affect memory in anyway [92].
The results from these described experiments demonstrated
that rimonabant produced various effects dependent upon the
route of administration, the timing of infusion, and the dose of
the drug. Similarly, Lichtman reported an improvement of
memory acquisition induced by administration of
SR141716A [93]. Likewise, Wolff and Leander showed the
enhancement of the consolidation processes when the animals
were tested in the RAM test [89]. Furthermore, Wolff and
Leander [89] proved a dose of 1.0 mg/kg of SR141716A to
be effective. The higher dose of 3.0 mg/kg did not improve the
consolidation, what is consistent with the results obtained by
Lichtman [93] in the same task. Pro-cognitive effects of
rimonabant were also shown in the experiments performed
by Takahashi et al. [88]. Administration of 1.0 mg/kg of
rimonabant produced an improvement in memory acquisition
and consolidation in the ETM task. Neither lower (0.5 mg/kg)
nor higher (2.0 mg/kg) doses were able to improve acquisi-
tion. Additionally, facilitation of short-term olfactory memory
in the social recognition test was described by Terranova et al.
[88]. On the other hand, Marsicano and colleagues failed to
prove any effect of rimonabant on the consolidation of aver-
sive memories [94]. This result may be accounted to the dif-
ferent mouse strain. The single dose used by Marsicano et al.
[94] was also higher than the maximum dose used in the
studies described previously.
AM251 is a member of the same CB group of
diarylopyrazoles as SR141716A, presenting the features of
CB1 receptor antagonist and inverse agonist [4]. The post-
training administration of AM251 interfered consolidation of
memory-related processes in the step-through IA task or CFC
task [82, 87]. De Oliveira Alvares et al. [81] investigated the
effects of intra-hippocampal administration of AM251 in two
behavioral tasks: the IA and the open field (OF) habituation
task. The results indicated that AM251 exerted a disruptive
effect on memory consolidation in the IA test, but not in the
OF habituation test. Similarly, Kruk-Slomka and Biala [63]
confirmed that an acute injection of AM251 improved the
short-term and long-term memory stages (acquisition, consol-
idation, and/or retrieval) in the IA task. The effect seemed to
be purely mnemonic since the drug showed no motor perfor-
mance effects, which could favor a false positive for the inter-
mediate dose in the IA test session. It needs to be highlighted
that the amnestic effect took place with the lower, more selec-
tive dose, not with the higher one (that one could bind to the
non-specific targets in the hippocampus). The different re-
sponses observed in two behavioral tasks require explanation.
The findings of the study suggest that hippocampal
endocannabinoids are not acting upon the consolidation of
the OF habituation task. The fact that the OF was not recruited
and the IAwas sensitive to AM251 raises the possibility that
this system requires some degree of aversiveness or alertness
to be recruited. The impairing effect of AM251 on memory
consolidation was also confirmed by Bucherelli et al. in 2006
[87]. De Oliveira Alvares and colleagues replicated the previ-
ous findings [80]. Afterwards, Bialuk and Winnicka [4] per-
formed a study in an attempt to determine the influence of
different doses of AM251 on recognition memory. In order
to evaluate the effects of AM251 on acquisition of informa-
tion, the drug was given 15 min before learning trial, and to
establish its influence on consolidation of information, it was
injected immediately after the trial in the ORT. The results of
the study indicated that AM251 significantly improved both
acquisition and consolidation of information; however, these
effects were observed only when dose of 1 mg/kg was admin-
istered. Higher doses did not exert any influence on it. The
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memory-improving effect is in an agreement with the results
obtained in experiments with SR141716A [4].
Interesting experiments in the context of our paper seem to
be the studies of Tan et al. [95]. The authors used CB antag-
onist, agonist, and reuptake inhibitor, AM251,WIN 55,212-2,
and AM404, respectively. The substances were administered
bilaterally as an intra-BLA and intra-prelimbic (intra-PLC)
microinfusion in rats. The results indicated that pharmacolog-
ical inhibition of intra-BLA CB1 receptor transmission dose-
dependently blocked the acquisition of olfactory fear memory,
simultaneously leaving unaffected recall and consolidation of
these memories in an olfactory fear conditioning procedure. In
addition, activation of CB1 receptor transmission or inhibition
of the endocannabinoid reuptake within BLA strongly poten-
tiated the acquisition of fear memory. Moreover, fear memory
formation, mediated by CB1 receptor, was blocked when the
medial prefrontal cortex (mPFC) was pharmacologically
inactivated before intra-BLA activation of CB1. These find-
ings are consistent with the report presented by Campolongo
et al., which showed that intra-BLA activation of CB1 recep-
tors can potentiate the encoding of associative memory for IA
learning [82]. Previous studies conducted by Roche et al. [96]
indicated that intra-BLA blockade of CB1 receptor transmis-
sion with rimonabant inhibits the formation of context-
dependent fear memory. Overall, the previously mentioned
findings suggest that CB1 receptor-dependent transmission
within the BLA can influence the magnitude of emotional
memory encoding. Additionally, the memory-improving ef-
fects of AM251 observed in this study were in agreement with
the results obtained by Riedel and Davies [97]. They have
reported that while the CB1 receptor agonists impair memory
formation, the CB1 receptor antagonists reverse these deficits
or act as memory enhancers.
Lin et al. studied the effects of another CB1 receptor antag-
onist AM281 on the formation of contextual fear memory in
adult mice [98]. AM281 (2.5 mg/kg) was injected both intra-
peritoneally and intra-hippocampally to assess the influence on
memory acquisition. These results indicate that CB1 receptor-
mediated signaling within the area of hippocampus negatively
regulates the acquisition in contextual fear memory task. Thus,
AM281 seems to be a good candidate for memory enhance-
ment; however, further studies in animal models of cognitive
dysfunctions are still required. In the context of this subject, it
should be noted thatWise et al. decided to determine the effects
of a relatively novel and potent CB1 receptor antagonist CE on
memory processes. CE is structurally distinct from rimonabant.
Wise and colleagues observed that CE significantly enhanced
memory consolidation in the RAM procedure [99].
As we described previously, the influence of the CB1 re-
ceptor ligands on memory and learning processes has been
widely documented by various experiments and clinical stud-
ies. Although CB1 receptor ligands are able to improve as
well as to impair memory, each of them affects memory in a
different way. Such contradictory findings may be connected
with differences in behavioral tasks used, handling proce-
dures, e.g., time of drug administration, the kind of drug treat-
ment, or other experimental conditions, as well as doses and
CB compounds selected. Therefore, future studies may help to
discover and describe the precise role and character of differ-
ent CB1 receptor compounds (Table 2).
The Role of CB Receptor in the Memory-Related
Responses in Animal Models of Memory: CB2
Receptor Agents
The specific impact of CB2 receptor ligands on the cognition-
related processes seems to be more complex and still not pre-
cisely explored. In this part of the present elaboration, we can
discuss only few results concerning the effects of the CB2
receptor ligands on memory and learning.
The results of the studies suggest that the activation of CB2
receptors evokes diverse effects depending on the brain area.
Chronic stimulation of CB2 receptors in the hippocampus
increases excitatory synaptic transmission [26], and simulta-
neously, deletion of CB2 in the same brain structure leads to
reduction in dendritic spine density [25]. Chronic activation of
CB2 also increases GABA-A receptor expression [28], yet it
does not affect the inhibitory synaptic transmission in the hip-
pocampus. CB2 receptor agonists reduce membrane excitabil-
ity of cortical neurons [35] leaving hippocampal neurons un-
affected [26]. CB2 receptor agonists also increase chloride
conductance [35].
JWH133 is a selective CB2 receptor agonist. Kruk-Slomka
et al. [64] established that the lower dose of JWH133
(0.5 mg/kg) exerted no influence on the acquisition but en-
hanced the consolidation of long-term memory in the PA test.
JWH133 (at higher doses of 1.0 and 2.0 mg/kg) improved the
acquisition or consolidation of long-term memory. An acute
pretraining and post-training administration improved
memory-related responses evaluated in the PA test.
The CB2 antagonist AM630 is one of the most studied
exogenous CB receptor ligands. It acts as an inverse agonist
both at CB2 and CB1 receptor sites [100]. Kruk-Slomka et al.
[64] revealed that AM630 significantly improved memory.
The higher doses of AM630 (2.0 and 3.0 mg/kg) induced
statistically significant increase in antioxidant properties of
brain tissue and evoked long-term memory improvement in
behavioral test. However, the lower dose (0.5 mg/kg) was
found inactive; it does not alter memory-related responses in
the PA test in mice.
It has been revealed in behavioral studies described previ-
ously that both a selective CB2 receptor agonist JWH133 and
a competitive CB2 receptor antagonist AM630 significantly
improved long-term memory acquisition and consolidation in
the PA test [64]. In contrast to these findings, García-Gutiérrez
Mol Neurobiol
























































































et al. [25] have shown that JWH133 enhanced memory con-
solidation, but AM630 impaired memory-related responses in
the step-down IA test.
The enhancement of memory caused by both CB2 antago-
nist and CB2 agonist obtained byKruk-Slomka et al. [64] may










































































receptor ligands, i.e., JWH133 and AM630. It needs to be
underlined that a CB2-selective agent AM630 acts as an in-
verse agonist rather than as a Bsilent^ antagonist. The inverse
efficacy at CB2 receptors and the CB2/CB1 affinity ratio has
been indicated for AM630 (CB2/CB1 affinity = 165); there-
fore, AM630 has been found to act as a low-affinity partial
agonist in some experiments but as a low-potency inverse
agonist in another study [101]. The pharmacological proper-
ties of AM630 are more complex. It has been revealed that
AM630 acts as an inverse agonist at CB2 receptors as well as
an inverse agonist at CB1 receptors [102]; therefore, it may be
proposed that both agonist and antagonist of CB2 receptors
used in this study may improve memory and learning process-
es through CB1 as well as CB2 receptors. Further experiments
are required to explain this phenomenon.
To sum up, it should be mentioned that the specific impact
of CB2 receptor ligands on the cognition-related processes
seems to be more complex and still not precisely evaluated.
Similarly as CB1 receptor ligands, CB2 receptor ligands are
able to attenuate as well as facilitate memory and learning
processes. These different memory effects may be associated
mainly with pharmacokinetic properties of tested CB2 recep-
tor ligands as well as with antioxidant properties, exhibited by
both agonists and antagonist of these receptors (Table 3).
The Role of CB Receptor in the Memory-Related
Responses in Animal Models of Memory: CB
Receptor Deficiency
In order to establish the role of CB receptors more accurate
and disentangle the role of endocannabinoid system in mem-
ory formation, two strands of research have been implement-
ed: knockout mice deficient for CB receptor as well as afore-
mentioned administration of selective CB receptor antagonist.
Litvin et al. used a genetic knockout of CB1 receptors
(CB1KOS) in order to evaluate the role of these receptors in
memory formation processes [9]. The CB1KOS and the ani-
mals that received the CB1 antagonist AM251 showed en-
hanced levels of social memory relative to their respective
controls in a social discrimination test. These results empha-
size the role of CB1 receptors in memory formation. The
endocannabinoids bind to CB1 receptors in various brain re-
gions to modulate behavioral functions in relation to cogni-
tion, emotionality, and stress [12, 103]. These results delineate
the effects of CB1 receptor inactivation by utilizing conver-
gent genetic and pharmacological approaches. These paths of
experiments produce similar behavioral profiles resulting in
enhancing memory acquisition in the social discrimination
test with some differences, which can attest to discrepancies
between these manipulations. These results extend the role of
the ECS inmood andmemory [104] and simultaneously are in
line with the reports describing a specific role of CB1 receptor
in these processes [105]. The results achieved by Litvin et al.
[9] of increased cognitive abilities in the CB1KOS mice are
consistent with the previous reports describing enhanced cog-
nitive performance in several other tests like active avoidance
memory [106], CFC [107], and ORT [108, 109]. It has been
also reported that CB1-deficient mice display normal acquisi-
tion and impaired extinction of both spatial reference memory
[110, 111] and cued fear memory [59]. CB1KOS mice also
present reduced working memory [58]. Although the param-
eters of PA concerning the memory-related effects stayed un-
affected [36], the contextual fear memory was reported both to
be enhanced and to be impaired [56].
Similarly, for a complete understanding of the mechanism
underlying the action of CB2 receptors, it will be necessary to
determine the role of CB2 receptors in regulating various
properties of synaptic transmission. It also needs to be evalu-
ated whether the affected immune functions in CB2 receptor
genetic knockout mice (CB2KOS) influence the processes
involved in learning and memory. Li and Kim [112] utilized
both CB2-deficient mice and acute blockade of CB2 receptors
by AM630. The results indicated that the inhibition of CB2 by
a specific CB2 receptor antagonist AM630 had no effect on
memory acquisition in contrast to the knockout of CB2 recep-
tors. The findings indicated that acquisition of spatial working
memory evaluated in Y-maze in CB2KOS was enhanced in
comparison to mice examined in the WMT. The results also
indicated that CB2 receptors play diverse roles in regulating
memory. Thus, taken together, the results imply that the ef-
fects of CB2 receptor blockade (either through genetic defi-
ciency or pharmacological inhibition) are variable. Acute
blockade with AM630 exerts no effect on memory acquisi-
tion, implying that downregulation of CB2 receptors needs to
be prolonged to induce such effects [112].
These all findings indicate that normal acquisition of cued
fear memory is common for both CB1- and CB2-deficient
mice, but alterations in the working memory are opposite.
Overall, conclusion leads to the statement that CB1 and CB2
receptors play a role in modulation of memory processes.
Once the role of each type of receptor is fully characterized,
either CB1 or CB2 receptor can be selectively targeted for
pharmacological therapeutics to induce the desired results
and avoid the unwanted ones.
The Role of Endocannabinoids
in the Memory-Related Responses in Animal Models
of Memory
As we mentioned previously, AEA and 2-AG are two main
endocannabinoids in the CNS. Lin et al. [2011] examined the
impact of AM404, an AEA reuptake inhibitor, on the acqui-
sition of memory in mice using the CFC paradigm [98].
AM404 was administered into the dorsal hippocampus
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15 min prior to the conditioning session. The outcome of the
experiment indicated significant suppression of the fear mem-
ory. Moreover, Lin et al. [98] confirmed that the inhibitory
effect of AM404 on fear memory formation was mediated
by the activation of CB1 receptor. Taken together, they con-
cluded that AEA-mediated activation of CB1 receptor contrib-
utes negatively to the acquisition of contextual fear memory.
The level of AEA may be also increased by the usage of
FAAH inhibitor. FAAH inhibitor, URB597, increases AEA
levels at those neuronal sites and regions of the brain, where
AEA is synthesized and released, producing a neuron-specific
activation of CB1 receptor in those areas. On the contrary,
systemic administration of CB1 receptor agonist such as
Δ9-THC produces global activation of all CB1 receptors in
the whole brain [68].
Mazzola et al. [68] accomplished the inhibition of FAAH
by administering URB597 [68]. The effects of URB597 were
studied both alone and after pretreatment with rimonabant in
the PA paradigm. The findings of this study revealed that
URB597 (0.1–1.0 mg/kg), injected 40 min before the learning
trial, had a significant enhancing effect on memory acquisi-
tion. Further testing demonstrated that the memory-enhancing
effects were inhibited after the pretreatment with 1.0 mg/kg
rimonabant. These results are consistent with the previous
studies suggesting that FAAH inhibition enhances place mem-
ory acquisition in the WMT procedure [113]. The effects of
URB597 on acquisition were also studied [114]. In this exper-
iment, the authors evaluated the effects and interaction be-
tween URB597 and WIN 55,212-2 using the PA test [114].
Learning and memory impairment was elicited by WIN
55,212-2 (1.0 mg/kg) administered 30 min before the acqui-
sition trial in rats. URB597 (0.1, 0.3, 1.0 mg/kg) or
SR141716A (1.0 mg/kg) was injected 10 min before WIN
55,212-2 or URB597, respectively. The results indicated that
URB597 at the dose of 0.3 and 1 mg/kg enhanced memory
acquisition in the PA test. The dose of 0.1 mg/kg exerted no
effects. The cognitive-enhancing effects were blocked by
SR141716A. This study also revealed that SR141716A





































injected separately had no effects on cognition. In conclusion,
these findings suggest that URB597 has potential to protect
against memory deficits produced by CBs. The results of this
study are in accordance with the other studies in which stim-
ulation of the endogenous CB signaling with URB597 en-
hances acquisition in the PA learning and aversively rein-
forced spatial memory tasks [68, 86, 113].
As CB1 agonists exert amnestic effects and URB597 in-
creases endogenous level of CB1 agonist AEA, findings that
URB597 enhances memory and this improvement can be
inhibited by CB1 receptor antagonist are puzzling. It is possible
that learning improvement produced by FAAH inhibitor is not
actually mediated by CB1 receptor but is blocked by
SR141716A due to its inverse agonist effects on CB1 receptor.
De Oliveira et al. investigated the role of AEA upon the
different phases of memory processing [37]. The results were
evaluated in the step-down IA task. The findings of the study
indicated that post-training infusion of anandamide facilitated
memory consolidation. It is worth noting that only the small
dose of AEA infused into the dorsal hippocampus of the male
Wistar rats exerted enhancing effect on memory. Any
memory-enhancing effect was observed after the administra-
tion of higher doses. The lack of its efficacy at higher doses
may be explained by its binding to different areas. At the low
dose, AEA may mainly target the CB1 receptors.
It should also be noted that the effects of FAAH inhibitor,
OL-135, and of genetic deletion of FAAH in mice were stud-
ied [115]. Both of these manipulations enhanced the acquisi-
tion of spatial learning in the WMT. This enhancement was
inhibited by pretreatment with rimonabant, suggesting the role
of CB1 receptors in the observed effects [113, 115, 116].
The research concerning FAAH inhibition opens a new
approach for developing medications that act indirectly by
enhancing the actions of endogenous lipid amide mediators,









































where they are synthesized and released. It is worth mention-
ing that FAAH inhibition might be related to a wide spectrum
of therapeutic actions and could also share some of the adverse
effects of cannabis; therefore, it is prominent that URB597
possesses potentially beneficial properties and displays no in-
dication of liability for abuse or dependence. Therefore, it has
been suggested to improve therapeutic interventions in mem-
ory deficit cases (Table 4).
Conclusion
The results of the studies described in this elaboration sum-
marize the impact of CBs on different stages of memory for-
mation. Many preclinical studies have evaluated the multidi-
rectional effects of compounds that directly affect the func-
tioning of the ECS (CB receptor ligands), as well as com-
pounds that modulate this function indirectly (inhibitors that
degrade endocannabinoids in the brain).
The modulation of the influence of the CB receptor ligands
on the different memory stages was widely evaluated in the
behavioral studies. Although both CB1 and CB2 receptor li-
gands are able to improve as well as to impair memory, each of
them affects memory in a different way and this subject is still
unexplored. Thus, further studies, not only behavioral exper-
iments, but also molecular (e.g., the assessment of the density
of the CB receptors in different brain areas: hippocampus,
prefrontal cortex) and biochemical (e.g., the influence of CB
receptor ligands on the neurotransmitter and metalloprotein-
ase levels in the brain or on the oxidative stress biomarkers)
are necessary. The results from these interdisciplinary experi-
ments may provide new information concerning the therapeu-
tically beneficial properties of the ECS in the brain.
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